efficacy and safety of rituximab in neuromyelitis optica: review of evidence
Authors
abstract
neuromyelitis optica (nmo) is an autoimmune inflammatory disease of the central nervous system with preferential involvement in the optic nerve and spinal cord with a widespread spectrum of clinical features; multiple therapeutic agents have been used with different results. recent evidence points to b?cell?mediated humoral immunity in the pathogenesis of nmo. rituximab targets the cd20 antigen on b?cells. treatment leads to profound b?cell depletion, principally over an antibody?dependent cell cytotoxicity mechanism. the aim of our study was to review clinical trials to elucidate the impact of rituximab on the relapse rate, expanded disability status scale (edss), and progression of disability in nmo. we performed a comprehensive review of all studies that evaluated clinical and paraclinical effects of rituximab on nmo. medline?pubmed, web of sciences, embase, and cochrane databases up to june 2016 included in our searches. in addition, reference lists from articles identified by search as well as a key review article to identify additional articles included in the study. rituximab targets the cd20 antigen on b?cells and decreases attack frequency and severity in patients with nmo; however, it does not remove attacks, even when modifying treatment to achieve b?cell depletion. most of the investigations revealed that edss significantly in all patients with rituximab treatment will be decreased after treatment with rituximab. no new or enlarged lesions or pathological gadolinium enhancement was observed in serial brain and spinal cord magnetic resonance imaging, except for those observed concomitantly with clinical relapses and the median length of spinal cord lesions was significantly reduced after therapy. rituximab targets the cd20 antigen and decreases attack frequency and severity in patients with nmo.
similar resources
Efficacy and Safety of Rituximab in patients with Neuromyelitis Optica Spectrum Disorders: A prospective observation in Iranian Cases.
full text
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
OBJECTIVE To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to improve rituximab monitoring and redosing. METHODS Multicenter retrospective study of 16 children with NMO/NMOSD receiving ≥2 rituximab courses. According to CD19 counts, events during rituximab were categoriz...
full textTreatment of neuromyelitis optica: an evidence based review.
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by severe optic neuritis and transverse myelitis, usually with a relapsing course. Aquaporin-4 antibody is positive in a high percentage of NMO patients and it is directed against this water channel richly expressed on foot processes of astrocytes. Due to the severity of NMO attacks and the high ri...
full textTreatment of Neuromyelitis Optica: Review and Recommendations.
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a ran...
full textDisease exacerbation after rituximab induction in neuromyelitis optica
Background. Rituximab (RTX), an anti-CD20 monoclonal antibody, was highly efficacious in reducing relapse rates in neuromyelitis optica (NMO) in several observational case series. Despite the favorable record, most series include 1 or more patients who experienced a relapse shortly after RTX induction. We review clinical histories of 6 patients with NMO treated at the New York University Multip...
full textMy Resources
Save resource for easier access later
Journal title:
journal of research in medical sciencesجلد ۲۱، شماره ۱۱، صفحات ۰-۰
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023